Sorafenib-Induced Tuberculosis Reactivation

Background: Sorafenib is a multikinase inhibitor with an established role in treating renal cell carcinoma and hepatocellular carcinoma. In vivo studies have demonstrated sorafenib’s inhibitory effects on various immune cells and cytokines which are essential to the maintenance of latency of granulomas in patients with latent tuberculosis infection. Case Report: A 74-year-old male with clear cell renal cell carcinoma with pulmonary metastases was treated with sorafenib to good effect. However, he developed productive cough, sweats and weight loss. A computed tomography scan of the thorax demonstrated right lower lobe consolidation and cavitation. Sputum analysis was positive for tuberculous smear and culture. A diagnosis of sorafenib-induced tuberculosis reactivation was made. Sorafenib was held and anti-tuberculous antibiotics were commenced, which led to symptomatic and radiographic improvement. Conclusion: The authors postulate that sorafenib could increase the risk of progression from latent to active tuberculosis, and urge vigilance and possible screening for latent tuberculosis in patients who are treated with sorafenib.

[1]  C. Porta,et al.  Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies? , 2011, Journal of Cancer.

[2]  O. Mir,et al.  Reactivation of tuberculosis during temsirolimus therapy , 2011, Investigational New Drugs.

[3]  C. Porta,et al.  Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. , 2010, European journal of cancer.

[4]  C. Leung,et al.  Tuberculosis in the global aging population. , 2010, Infectious disease clinics of North America.

[5]  JoAnne L. Flynn,et al.  Understanding Latent Tuberculosis: A Moving Target , 2010, The Journal of Immunology.

[6]  F. Mayer,et al.  The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro1 , 2009, The Journal of Immunology.

[7]  P. Postmus,et al.  Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia , 2009, European Respiratory Journal.

[8]  P. Meylan,et al.  Peritoneal tuberculosis after imatinib therapy. , 2009, Archives of internal medicine.

[9]  Edwin P Hui,et al.  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Noelke,et al.  MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib , 2009, Molecular Cancer Therapeutics.

[11]  P. Brossart,et al.  Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.

[12]  J. Yim,et al.  Solid‐organ malignancy as a risk factor for tuberculosis , 2008, Respirology.

[13]  R. Song,et al.  Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation , 2008, Leukemia.

[14]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[15]  E. Waclawski Osteonecrosis of the jaw and bisphosphonates , 2006, BMJ : British Medical Journal.

[16]  B. Lane,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[17]  L. Duck,et al.  Osteonecrosis of the jaw and bisphosphonates. , 2005, The New England journal of medicine.

[18]  R. Horsburgh,et al.  Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.

[19]  D. Karnak,et al.  Reactivation of Pulmonary Tuberculosis in Malignancy , 2002, Tumori.

[20]  V. Ribrag,et al.  Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. , 2001, The New England journal of medicine.

[21]  John Chan,et al.  Tuberculosis: Latency and Reactivation , 2001, Infection and Immunity.